Editas Medicine Stock Today
| EDIT Stock | USD 2.01 0.09 4.69% |
PerformanceWeak
| Odds Of DistressAverage
|
Editas Medicine is selling for under 2.01 as of the 26th of February 2025; that is 4.69 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.75. Editas Medicine has 53 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2016 | Category Healthcare | Classification Health Care |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 82.55 M outstanding shares of which 17.09 M shares are currently shorted by private and institutional investors with about 6.83 trading days to cover. More on Editas Medicine
Moving against Editas Stock
Editas Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Gilmore MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEditas Medicine can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Editas Medicine's financial leverage. It provides some insight into what part of Editas Medicine's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Editas Medicine (EDIT) is traded on NASDAQ Exchange in USA. It is located in 11 Hurley Street, Cambridge, MA, United States, 02141 and employs 265 people. Editas Medicine is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 153.54 M. Editas Medicine conducts business under Biotechnology sector and is part of Health Care industry. The entity has 82.55 M outstanding shares of which 17.09 M shares are currently shorted by private and institutional investors with about 6.83 trading days to cover.
Editas Medicine currently holds about 452.56 M in cash with (132.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Editas Medicine Probability Of Bankruptcy
Ownership AllocationEditas Medicine holds a total of 82.55 Million outstanding shares. Over half of Editas Medicine's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Editas Ownership Details
Editas Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-12-31 | 1.5 M | |
| Balyasny Asset Management Llc | 2024-12-31 | 1.3 M | |
| Ubs Asset Mgmt Americas Inc | 2024-12-31 | 1.2 M | |
| Pictet Asset Manangement Sa | 2024-09-30 | 1.2 M | |
| Ubs Group Ag | 2024-12-31 | 1.1 M | |
| Jane Street Group Llc | 2024-12-31 | 1.1 M | |
| Aqr Capital Management Llc | 2024-12-31 | 1.1 M | |
| Monaco Asset Management | 2024-12-31 | 1.1 M | |
| Woodline Partners Lp | 2024-12-31 | 838.4 K | |
| Blackrock Inc | 2024-12-31 | 7.3 M | |
| Vanguard Group Inc | 2024-12-31 | 6.8 M |
Editas Medicine Historical Income Statement
Editas Stock Against Markets
Editas Medicine Corporate Management
| Bruce Eaton | Exec Officer | Profile | |
| Cristi Barnett | Corporate Relations | Profile | |
| Charlene JD | Executive Counsel | Profile | |
| Michelle Robertson | Principal CFO | Profile |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.